From 2019 to 2024, the market share of heat-not-burn tobacco products is predicted to expand by USD 22.22 billion, with a CAGR of 26.21 percent.
This market research report on heat-not-burn tobacco products gives useful insights into the post-COVID-19 influence on the current market, which will aid organisations in evaluating their business strategies. Furthermore, the market segmentation of heat-not-burn tobacco products by-product is also covered in this study.
The market study for heat-not-burn tobacco products also includes information on many market vendors, which are listed below:
- Vapor Tobacco Manufacturing LLC
- Shenzhen Yukan Technology Co. Ltd.
- Philip Morris International Inc.
- PAX Labs Inc.
- Korea Tobacco & Ginseng Corp.
- Japan Tobacco Inc.
- Imperial Brands Plc
- British American Tobacco Plc
- Ballantyne Brands LLC
- Altria Group Inc.
How does heat-not-burn tobacco work?
Traditional cigarettes burn up to 900°C, whereas heat-not-burn devices heat the tobacco to 350°C. Regardless, the temperature of heat-not-burn items still is high enough for dangerous compounds to vaporise and be inhaled.
What is the basic difference between heat-not-burn and any e-cigarettes?
Electronic cigarettes (e-cigarettes) differ from heat-not-burn goods in that the latter heat and evaporate a liquid, usually containing nicotine, whilst the former heats actual tobacco. Because IQOS does not burn the tobacco, Philip Morris asserts.
You can visit the website at sticks.sale to find a few latest smoking devices that are prevalent on the market these days.
Electronic cigarettes, also known as e-cigarettes, differ from heat-not-burn products in that the latter heat and evaporate a liquid, usually containing nicotine, whilst the former heats genuine tobacco.
Because IQOS will not burn tobacco, Philip Morris asserts that the product emits far fewer of the hazardous compounds contained in cigarette smoke. When compared to many traditional cigarettes, the business seeks to promote the product with the argument that it reduces risk of any tobacco-related disease.
According to Reuters, an FDA panel voted for rejecting this claim, stating that the firm had not produced enough evidence to establish that its product reduces illness risk when compared to cigarettes. The panel, however, agrees with the premise that the product emits fewer hazardous compounds than regular cigarettes.
Heat-and-burn products, in theory, are safer as they do not cause tobacco combustion. However, there is lack of evidence that users may face fewer risks as a result of utilising the items.
The majority of IQOS studies have been undertaken by Philip Morris, and independent researchers who may not be affiliated with the corporation are needed to determine the product’s safety.
Furthermore, it is yet unknown if enough smokers will convert to such products to provide a public health advantage.
The panel’s judgment is only a suggestion, and the FDA is going to make a decision within the coming months, on if Philip Morris may sell IQOS in the USA and what claims the business can make about their device.
According to Philip Morris, the product is already being sold in 29 nations. So they are now waiting for the final decision of the FDA to take further step.